HARRIS ISAIAH JR

SEC source: 0001225208-21-014394 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,015

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 34 and 107 of Cigna's proxy statement filed with the SEC on March 19, 2021.

SEC source: 0001225208-21-011977 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,716

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 34 and 107 of Cigna's proxy statement filed with the SEC on March 19, 2021.

SEC source: 0001225208-21-008829 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,445

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 34 and 107 of Cigna's proxy statement filed with the SEC on March 19, 2021.

SEC source: 0001225208-21-004292 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,223

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-014151 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,950

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-011219 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,676

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-008485 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,352

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 91 of Cigna's proxy statement filed with the SEC on March 13, 2020.

SEC source: 0001225208-20-004181 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,061

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-015089 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,747

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-012165 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,460

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-008809 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,087

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 32 and 93 of Cigna's proxy statement filed with the SEC on March 15, 2019.

SEC source: 0001225208-19-004401 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,699

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001567619-18-008658 · doc1.xml · derivative · entry 2

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $.25 Par Value · 23,260 shares

Expires not disclosed

F3 · security: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · kind: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · price: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.expiration_date: The phantom stock units described in Table II are credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

SEC source: 0001567619-18-008658 · doc1.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001567619-18-008717 · doc1.xml · derivative · entry 2

HARRIS ISAIAH JR · CIK 0001202287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,260

Underlying: Common Stock, $0.01 Par Value · 23,260 shares

Expires not disclosed

F3 · security: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · kind: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3 · price: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.exercise_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

F3 · derivative.expiration_date: Under the Merger Agreement, each phantom stock unit of Cigna credited under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

SEC source: 0001567619-18-008717 · doc1.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,370

F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

SEC source: 0001225208-18-016220 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,370

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001225208-18-013182 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,169

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001225208-18-010121 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,931

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's proxy statement filed with the SEC on March 16, 2018.

SEC source: 0001225208-18-005158 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,666

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 28 and 77 of Cigna's preliminary proxy statement filed with the SEC on March 2, 2018.

SEC source: 0001225208-17-018603 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,437

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2017.

F2 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001225208-17-018124 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,649

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001225208-17-015008 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,437

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2017.

F2 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001225208-17-014579 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,684

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001225208-17-010844 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,437

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 87 of Cigna's proxy statement filed with the SEC on March 18, 2017.

SEC source: 0001225208-17-005388 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,158

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016.

SEC source: 0001225208-16-042622 · doc4.xml · nonDerivative · entry 1

HARRIS ISAIAH JR · CIK 0001202287 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,856

F1 · balance_after: The reporting person's economic interest in Cigna securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of Cigna stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than Cigna stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for Cigna and pages 26 and 72 of Cigna's proxy statement filed with the SEC on March 18, 2016.